



Nebraska Medicaid  
Pharmaceutical and Therapeutics Committee Agenda  
**WEDNESDAY November 4, 2020**  
Virtual Webinar via Zoom

Public Attendees Meeting Registration Link:

[https://magellanhealth.zoom.us/webinar/register/WN\\_8BeHvnpFSiChqU32QOiNyQ](https://magellanhealth.zoom.us/webinar/register/WN_8BeHvnpFSiChqU32QOiNyQ)

- 08:55-9:00 a.m. Webinar opens for Public Attendees
- 09:00 a.m. Opening of Public Meeting and Call to Order  
Committee Business
- Introduction of New Committee Members
  - Roll Call
  - Conflict of Interest Updates
  - Approval of Meeting Minutes: May 13, 2020
  - Department Information
- 09:15-10:15 a.m. Public Testimony (for Products Recommended to be Non-Preferred)  
[https://nebraska.fhsc.com/Downloads/NE\\_PT\\_PublicTestimony\\_Guidelines.pdf](https://nebraska.fhsc.com/Downloads/NE_PT_PublicTestimony_Guidelines.pdf)  
<http://dhhs.ne.gov/Pages/Pharmacy-Drug-Testimony.aspx>  
\*Modifications to Public Testimony guidelines to accommodate for Virtual Webinar
- Public Testimony Registration Applications will only be accepted by email – No faxed/mailed requests will be accepted
  - If handouts are being provided, they must be submitted with testimony application, no later than the testimony deadline, for dissemination to the committee
- 10:15-12:55 p.m. Committee Closed Session (offline)- Public Webinar will close  
(Working Lunch, as needed)
- 12:55-1:00 p.m. Webinar re-opens for Public Attendees
- 1:00-5:00 p.m. Committee Open Session
- Consideration of Consent Agenda
  - Consideration of Therapeutic Class Reviews
- Break (if required)  
Adjournment

**Next meeting: Wednesday May 12, 2021**

**Consent Agenda: (Therapeutic Categories with Unchanged Recommendations)**

The following classes have no changes recommended by the Department and will all be voted on as a group, unless a class is removed from the Consent Agenda.

Alzheimer’s Agents  
Antihypertensives, Sympatholytics  
Antipsoriatics, Oral  
Anxiolytics  
Bile Salts  
Cough and Cold, Opiate  
Enzyme Replacement, Gauchers Disease  
Epinephrine, Self-Injected  
Erythropoiesis Stimulating Proteins  
Idiopathic Pulmonary Fibrosis  
Immunomodulators, Topical

Intranasal Rhinitis Agents  
Leukotriene Modifiers  
Methotrexate  
Movement Disorders  
Oncology, Oral – Skin  
Ophthalmic Antibiotic-Steroid Combinations  
Ophthalmic, Glaucoma Agents  
Otic Anti-Infectives & Anesthetics  
Steroids, Topical Medium  
Steroids, Topical Very High

**Therapeutic Class Reviews: (Therapeutic Categories with New Recommendations)**

Antihelmintics  
Anti-Allergens, Oral  
Antihistamines, Minimally Sedating  
Antihyperuricemics  
Antiparkinson’s  
Antipsoriatics, Topical  
Bronchodilators, Beta Agonist  
Colony Stimulating Factors  
COPD Agents  
Cytokine and CAM Antagonists  
Glucocorticoids, Inhaled  
Glucocorticoids, Oral  
Hemophilia Treatment  
Histamine II Receptor Blockers  
Immunomodulators, Asthma **(new)**  
Immunomodulators, Atopic Dermatitis  
NSAIDS  
Oncology, Oral- Breast

Oncology, Oral – Hematologic  
Oncology, Oral – Lung  
Oncology, Oral – Other  
Oncology, Oral – Prostate  
Oncology, Oral – Renal Cell  
Ophthalmic, Allergic Conjunctivitis  
Ophthalmic, Antibiotics  
Ophthalmic, Anti-Inflammatories  
Ophthalmic, Anti-  
Inflammatory/Immunomodulator  
Otic Antibiotics  
Progesterone (hydroxyprogesterone caproate)  
Sedative Hypnotics  
Sickle Cell Anemia Treatments **(new)**  
Steroids, Topical High  
Steroids, Topical Low  
Stimulants and Related Drugs  
Thrombopoiesis Stimulating Proteins **(new)**